PHEX, FGF23, DMP1 and beyond

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 4, 2008, Pages 357-362

  Strom, Tim M ^a,b   Jüppner, Harald ^c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Dentin matrix protein 1; Fibroblast growth factor 23; PHEX; Phosphate homeostasis

Indexed keywords

CALCITRIOL; DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; PHOSPHATE; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; DMP1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR; GLYCOPROTEIN; MEPE PROTEIN, HUMAN; PARATHYROID HORMONE; PHEX PROTEIN, HUMAN; PHOSPHOPROTEIN; SCLEROPROTEIN;

CHRONIC KIDNEY FAILURE; GENE MUTATION; GLYCOSYLATION; HOMEOSTASIS; HORMONE RESISTANCE; KIDNEY TUBULE ABSORPTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RENAL OSTEODYSTROPHY; REVIEW; URINARY EXCRETION; ANIMAL; BIOSYNTHESIS; BLOOD; GENETICS; HUMAN; METABOLISM; PARATHYROID GLAND; PHYSIOLOGY;

ANIMALS; CALCITRIOL; EXTRACELLULAR MATRIX PROTEINS; FIBROBLAST GROWTH FACTORS; GLYCOPROTEINS; HUMANS; KIDNEY FAILURE, CHRONIC; PARATHYROID GLANDS; PARATHYROID HORMONE; PHEX PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PHOSPHOPROTEINS;

EID: 55249095546     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282fd6e5b     Document Type: Review

References (72)

1. Eicher EM, Southard JL, Scriver CR, Glorieux FH. Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci U S A 1976; 73:4667-4671.
2. Lyon MF, Scriver CR, Baker LR, et al. The Gy mutation: another cause of Xlinked hypophosphatemia in mouse. Proc Natl Acad Sci U S A 1986; 83:4899-4903.
3. Nesbitt T, Coffman TM, Griffiths R, Drezner MK. Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. J Clin Invest 1992; 89:1453-1459.
4. Meyer RA Jr, Meyer MH, Gray RW. Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J Bone Miner Res 1989; 4:493-500.
5. Econs MJ, Drezner MK. Tumor-induced osteomalacia - unveiling a new hormone. N Engl J Med 1994; 330:1679-1681.
6. Bergwitz C, Roslin NM, Tieder M, et al. SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporterNaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet 2006; 78:179-192.
7. Lorenz-Depiereux B, Benet-Pages A, Eckstein G, et al. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodiumphosphate cotransporter gene SLC34A3. Am J Hum Genet 2006; 78: 193-201.
8. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001; 98:6500-6505.
9. The ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR Consortium. Nat Genet 2000; 26:345-348.
10. The HYP Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 1995; 11:130-136.
11. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 2006; 38:1248-1250.
12. Feng JQ, Ward LM, Liu S, et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006; 38:1310-1315.
13. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005; 14:385-390.
14. Topaz O, Shurman DL, Bergman R, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 2004; 36:579-581.
15. Magagnin S, Werner A, Markovich D, et al. Expression cloning of human and rat renal cortex Na/Pi cotransport. Proc Natl Acad Sci U S A 1993; 90:5979-5983.
16. Ichikawa S, Imel EA, Kreiter ML, et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007; 117:2684-2691.
17. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390:45-51.
18. Rowe PS, de Zoysa PA, Dong R, et al. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 2000; 67:54-68.
19. Shimada T, UrakawaI, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004; 314:409-414.
20. Larsson T, Marsell R, Schipani E, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004; 145:3087-3094.
21. Bai X, Miao D, Li J, et al. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 2004; 145:5269-5279.
22. Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113:561-568.
23. Liu S, Zhou J, Tang W, et al. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006; 291:E38-E49.
24. Sitara D, Razzaque MS, St-Arnaud R, et al. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol 2006; 169:2161-2170.
25. Yu X, Ibrahimi OA, Goetz R, et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 2005; 146:4647-4656.
26. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444:770-774.
27. Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor23 signaling by klotho. J Biol Chem 2006; 281:6120-6123.
28. Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hormone Klotho. Science 2005; 309:1829-1833.
29. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117:4003-4008.
30. Krajisnik T, Bjorklund P, Marsell R, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007; 195:125-131.
31. Kuro-o M. Klotho as a regulator of oxidative stress and senescence. Biol Chem 2008; 233-241.
32. White KE, Jonsson KB, Carn G, et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 2001; 86:497-500.
33. White KE, Carn G, Lorenz-Depiereux B, et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001; 60:2079-2086.
34. ShimadaT,MutoT,Urakawa I, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002; 143:3179-3182.
35. Benet-Pages A, Lorenz-Depiereux B, Zischka H, et al. FGF23 is processed by proprotein convertases but not by PHEX. Bone 2004; 35:455-462.
36. Liu S, Guo R, Simpson LG, et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003; 278:37419-37426.
37. Kato K, Jeanneau C, Tarp MA, et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 2006; 281:18370-18377.
38. Jin W, Fuki IV, Seidah NG, et al. Proprotein convertases are responsible for proteolysis and inactivation of endothelial lipase. J Biol Chem 2005; 280:36551-36559.
39. Cao J, Rehemtulla A, Pavlaki M, et al. Furin directly cleaves proMMP-2 in the trans-Golgi network resulting in a nonfunctioning proteinase. J Biol Chem 2005; 280:10974-10980.
40. Hesse M, Frohlich LF, Zeitz U, et al. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol 2007; 26:75-84.
41. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19:429-435.
42. Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counterregulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17:1305-1315.
43. Kolek OI, Hines ER, Jones MD, et al. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renalgastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 2005; 289:G1036-G1042.
44. Shimada T, Yamazaki Y, Takahashi M, et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005; 289:F1088-F1095.
45. Masuyama R, Stockmans I, Torrekens S, et al. Vitamin D receptor in chon-drocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest 2006; 116:3150-3159.
46. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348:1656-1663.
47. Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002; 87:4957-4960.
48. Imel EA, Hui SL, Econs MJ. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 2007; 22:520-526.
49. Sitara D, Razzaque MS, Hesse M, et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004; 23:421-432.
50. Lu Y, Liu S, Yu S, et al. The 57 kDa C-terminal fragment of Dentin Matrix Protein 1 (DMP1) retains all biological activity: Osteocytic regulation of Pi homeostasis through FGF23. J Bone Miner Res 2007; 22 (Suppl. 1):1296.
51. Qin C, Baba O, Butler WT. Posttranslational modifications of sibling proteins and their roles in osteogenesis and dentinogenesis. Crit Rev Oral Biol Med 2004; 15:126-136.
52. Ye L, Mishina Y, Chen D, et al. Dmp1-deficient mice display severe defects in cartilage formation responsible for a chondrodysplasia-like phenotype. J Biol Chem 2005; 280:6197-6203.
53. Qin C, Brunn JC, Cook RG, et al. Evidence for the proteolytic processing of dentin matrix protein 1. Identification and characterization of processed fragments and cleavage sites. J Biol Chem 2003; 278:34700-34708.
54. Steiglitz BM, Ayala M, Narayanan K, et al. Bone morphogenetic protein-1/ Tolloid-like proteinases process dentin matrix protein-1. J Biol Chem 2004; 279:980-986.
55. Bowe AE, Finnegan R, Jan de Beur SM, et al. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 2001; 284:977-981.
56. Lu Y, Liu S,Xie Y, et al. Use of the transgenic approach to determine the role of DMP1 in phosphate regulation. J Musculoskelet Neuronal Interact 2007; 7:309.
57. Yang W, Lu Y, Kalajzic I, et al. Dentin matrix protein 1 gene cis-regulation: use in osteocytes to characterize local responses to mechanical loading in vitro and in vivo. J Biol Chem 2005; 280:20680-20690.
58. Harris SE, Gluhak-Heinrich J, Harris MA, et al. DMP1 and MEPE expression are elevated in osteocytes after mechanical loading in vivo: Theoretical role in controlling mineral quality in the perilacunar matrix. J Musculoskelet Neuronal Interact 2007; 7:313-315.
59. Liu S, Brown TA, Zhou J, et al. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 2005; 16:1645-1653.
60. Gowen LC, Petersen DN, Mansolf AL, et al. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 2003; 278:1998-2007.
61. Rowe PS, Kumagai Y, Gutierrez G, et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 2004; 34:303-319.
62. Ecarot B, Desbarats M. 1,25-(OH)2D3 down-regulates expression of Phex, a marker of the mature osteoblast. Endocrinology 1999; 140: 1192-11 99.
63. Argiro L, Desbarats M, Glorieux FH, Ecarot B. Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone. Genomics 2001; 74:342-351.
64. Okano T, Tsugawa N, Hirami C, Kato S. Functional properties of cultured normal and vitamin D receptor knockout mice calvarial osteoblasts. J Bone Miner Res 2003; 18:S141.
65. Dobbie H, Unwin RJ, Faria NJ, Shirley DG. Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption. Nephrol Dial Transplant 2008; 23:730-733.
66. Harris S, Gluhak-Heinrich J, Harris M, et al. MEPE is overexpressed in osteocytes of the DMP1 (Dentin Matrix Protein 1) null mouse, contributing to the hypophosphatemia and osteomalacia. J Bone Miner Res 2005; 20 (Suppl. 1):SA462.
67. Boileau G, Tenenhouse HS, Desgroseillers L, Crine P. Characterization of PHEXendopeptidase catalytic activity: identification of parathyroid- hormonerelated peptide107-139 as a substrate and osteocalcin, PPi and phosphate as inhibitors. Biochem J 2001; 355:707-713.
68. Campos M, Couture C, Hirata IY, et al. Human recombinant endopeptidase PHEX has a strict S1' specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein. Biochem J 2003; 373:271-279.
69. Guo R, Rowe PS, Liu S, et al. Inhibition of MEPE cleavage by Phex. Biochem Biophys Res Commun 2002; 297:38-45.
70. Martin A, David V, Laurence JS, et al. Degradation of MEPE, DMP1 & release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 2008; 149:1757-1772.
71. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16:2205-2215.
72. LarssonT, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64:2272-2279.